GlassScriptPhysician profile
Supriya Kohli
NPI 1194019570
$24,919.29
in general payments reported to CMS, 2019-2025
59 companies · $4,195 in 2025
The $4,195 reported for 2025 was more than what 83% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,908 · 2020: $2,470 · 2021: $3,779 · 2022: $3,838 · 2023: $3,164 · 2024: $4,566 · 2025: $4,195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $75.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,849.11 |
| Education | $75.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $3,238.50 | 2019-2025 | Briviact, Rystiggo, Fintepla |
| Abbvie INC. | $2,809.20 | 2021-2025 | |
| Amgen INC. | $1,404.48 | 2019-2025 | Aimovig, Uplizna |
| Sk Life Science, INC. | $1,181.10 | 2020-2025 | Xcopri |
| Pfizer INC. | $1,060.49 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $1,015.72 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $950.01 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Lilly USA, LLC | $929.04 | 2019-2025 | Amyvid, Emgality, Kisunla |
| Supernus Pharmaceuticals, INC. | $919.61 | 2019-2025 | Qelbree, Oxtellar Xr |
| Mdd US Operations, LLC | $914.92 | 2019-2025 | Gocovri, Gocovri |
| Jazz Pharmaceuticals INC. | $868.25 | 2022-2025 | |
| Acadia Pharmaceuticals INC | $822.06 | 2019-2025 | Nuplazid |
| Argenx US, INC. | $809.11 | 2022-2025 | Vyvgart |
| Allergan, INC. | $803.87 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $646.20 | 2019-2022 |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $612.25 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Biohaven Pharmaceutical Holding Company LTD. | $607.96 | 2022 | |
| Neurocrine Biosciences, INC. | $503.54 | 2020-2025 | Ingrezza, Ongentys |
| Lundbeck LLC | $412.61 | 2019-2025 | Vyepti, Rexulti |
| Eisai INC. | $369.38 | 2019-2025 | |
| Neurelis, INC. | $308.15 | 2021-2025 | Valtoco |
| Biogen, INC. | $289.05 | 2021-2025 | Leqembi, Vumerity, Plegridy |
| Adamas Pharmaceuticals, INC. | $283.44 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $264.73 | 2024-2025 | Hyqvia |
| Boston Scientific Corporation | $258.66 | 2019-2025 | Vercise, General - Dbs |
| Biohaven Pharmaceuticals, INC. | $255.81 | 2021 | |
| Amneal Pharmaceuticals LLC | $210.31 | 2021-2025 | Crexont, Rytary |
| Astrazeneca Pharmaceuticals LP | $183.74 | 2021-2023 | Andexxa |
| Arbor Pharmaceuticals, INC. | $181.24 | 2019-2022 | |
| Azurity Pharmaceuticals, INC. | $160.22 | 2023-2025 | Horizant, Horizant |
| Akcea Therapeutics, INC. | $143.91 | 2019-2020 | |
| Janssen Biotech, INC. | $123.09 | 2025 | |
| Acorda Therapeutics, INC | $110.10 | 2019-2021 | |
| Aprecia Pharmaceuticals, LLC | $109.99 | 2020-2023 | Spritam |
| Alnylam Pharmaceuticals INC. | $105.95 | 2019-2024 | Onpattro |
| Sumitomo Pharma America, INC. | $100.41 | 2023-2024 | Aptiom |
| Grifols USA, LLC | $90.18 | 2019-2025 | Gamunex-C |
| Scilex Pharmaceuticals INC. | $78.21 | 2023-2024 | Ztlido |
| Tg Therapeutics, INC. | $72.84 | 2023-2024 | |
| Impel Pharmaceuticals INC. | $64.23 | 2023 | Trudhesa |
| Otsuka America Pharmaceutical, INC. | $64.17 | 2023-2025 | Rexulti, Nuedexta |
| Avion Pharmaceuticals | $62.08 | 2022 | |
| Vanda Pharmaceuticals INC. | $50.03 | 2024-2025 | Ponvory |
| Idorsia Pharmaceuticals US INC | $48.99 | 2022-2023 | Quviviq |
| Emd Serono, INC. | $48.10 | 2019 | |
| Genzyme Corporation | $45.57 | 2021 | |
| Avanir Pharmaceuticals, INC. | $35.02 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $34.56 | 2022 | |
| Aucta Pharmaceuticals, INC. | $33.00 | 2025 | Motpoly Xr |
| Janssen Pharmaceuticals, INC | $29.96 | 2022 | |
| Upsher-Smith Laboratories LLC | $28.43 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $26.43 | 2022-2024 | Onzetra Xsail |
| Abbott Laboratories | $25.85 | 2025 | Infinity |
| Nevro Corp. | $24.25 | 2024 | Senza |
| Axsome Therapeutics, INC. | $23.34 | 2025 | Symbravo |
| Impel Pharmaceuticals LLC | $22.09 | 2025 | Trudhesa |
| Inspire Medical Systems, INC. | $17.82 | 2024 | Inspire |
| Kyowa Kirin, INC. | $14.47 | 2024 | Nourianz |
| Assertio Therapeutics, INC. | $12.57 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Supriya Kohli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.